If you've tried antidepressant after antidepressant and still don't feel like yourself, you're not alone, and you're not out of options.

Comparing IV ketamine vs Spravato is one of the most common questions we hear from people who've reached this point in their care. Both come from the same family of medication and work faster than a typical pill. One of their main aspects is that both IV ketamine and Spravato are used to help people move through treatment-resistant depression when standard antidepressants haven't been enough. But the answer to "which one is right for me" isn't as simple as "they're the same drug," and it deserves more than a quick internet search.

IV Ketamine vs Spravato: What's the Difference?

IV ketamine and Spravato differ in formulation and approval status. IV ketamine is an off-label infusion using the full ketamine molecule, while Spravato (esketamine) is an FDA-approved nasal spray containing just one half of that molecule. Research suggests both may bring relief within hours to days, but

• Differ considerably in cost
• Insurance coverage, and
• How closely each session is monitored.

Neither is universally "better." The right fit depends on your diagnosis, your budget, and what your psychiatrist recommends for you specifically.

‍

Before we go further, we want you to hear this from the source. Read the FDA's detailed review of esketamine.

First of all, IV ketamine and Spravato are treatments used for depression that hasn’t responded to traditional antidepressants.

IV ketamine is a generic anesthetic medication delivered through a slow intravenous drip, typically in a supervised clinical setting. It's off-label ketamine use for mood disorders, meaning the FDA approved ketamine for anesthesia in 1970, not specifically for depression. (FDA drug label database)

Spravato (esketamine) is a branded esketamine nasal spray manufactured by Janssen. It received FDA approval in 2019, making it an FDA-approved treatment specifically for treatment-resistant depression when paired with an oral antidepressant.

People compare IV ketamine vs. esketamine because they come from the same chemical family and both act faster than typical antidepressants.

Here's a quick summary of who each one is generally designed for:

Ketamine has been an FDA-approved anesthetic since 1970, but its use for depression is still considered off-label, even though it's widely used in psychiatric clinics under physician supervision.

‍

Is Spravato the Same as Ketamine?

Not exactly, though it's derived from it.

Regular ketamine is a "racemic" molecule, meaning it holds two mirror-image halves: R-ketamine and S-ketamine. Esketamine, the active ingredient in Spravato, is only the S-ketamine half, isolated and purified into its own antidepressant medication. (Correia-Melo et al., 2020, PubMed)

So is Spravato ketamine? Chemically, yes, it's built from the same parent compound. Practically, no, it's a distinct, patented formulation with its own FDA approval, dosing schedule, and delivery method.

What they share:

• Both act on the same brain receptor system
• Both can bring rapid antidepressant effects
• Both carry similar short-term side effects like dissociation

Where they differ:

• Ketamine (IV) contains the full racemic molecule; Spravato contains only esketamine
• Spravato is FDA-approved; IV ketamine for depression is off-label
• Spravato is a nasal spray; IV ketamine is delivered intravenously

This distinction matters because FDA approval status shapes how each drug is regulated, monitored, priced, and covered by insurance, all of which we'll walk through below.

IV Ketamine vs Spravato: Side-by-Side Comparison

Here's the fastest way to see how ketamine and Spravato compare across the factors that matter most to patients.

Sources for these figures are cited throughout the effectiveness, side effects, and cost sections below.

How IV Ketamine Infusions and Spravato Treatments Work

Both treatments work by targeting a different brain pathway than standard antidepressants, which is why they tend to act faster.

Understanding the science helps explain why your medical supervisor might recommend one instead of awaiting another SSRI trial.

Both ketamine and esketamine block the NMDA receptor, a glutamate receptor involved in learning and mood regulation. This sets off a cascade that increases glutamate signaling and activates AMPA receptors, which appear to stimulate neuroplasticity, your brain's natural ability to form new neural connections and, in many ways, rewire hope. (Duman et al., glutamate/synaptic plasticity review, PMC)

This is fundamentally different from how SSRIs work. SSRIs raise serotonin levels gradually and typically take 2 to 6 weeks to show meaningful effects. Ketamine and esketamine, by contrast, may improve mood within hours to a few days for many people, according to research on their rapid antidepressant effects.

• SSRIs: a slow, gradual buildup of serotonin, weeks to feel a difference
• Ketamine/esketamine: rapid NMDA receptor blockade, a glutamate surge, and plasticity changes that can begin within hours

Medical disclaimer: This article is for informational purposes only and is not medical advice. Please talk with a qualified healthcare provider before starting, stopping, or changing any treatment or suppleme

Spravato vs IV Ketamine: How Are They Administered?

The treatment experience itself is one of the biggest practical differences, and honestly, it's often what tips someone's decision one way or the other.

With an IV infusion, you'll sit in a reclined chair while a nurse or physician administers ketamine through an IV line over roughly 40 to 60 minutes, monitoring your heart rate and blood pressure throughout. Afterward, you'll rest for another 15-30 minutes before being cleared to leave with a driver.

With Spravato, you self-administer the nasal spray under direct staff supervision, then remain onsite for a mandatory 2-hour observation period required by the FDA's REMS (Risk Evaluation and Mitigation Strategy) program. Read up more on FDA Spravato REMS requirements.

Comparing the two treatments’ infusion process:

• Appointment length: IV ketamine, roughly 1-1.5 hours total; Spravato, roughly 2-3 hours due to REMS monitoring
• Frequency: Both typically begin with twice-weekly sessions for the first few weeks
• Take-home use: Neither can be taken home; both require an in-clinic visit
• After your session: You cannot drive yourself home from either treatment the same day

Neither is something you can administer on your own at home. Both require a REMS-certified or clinically supervised setting because of the sedation and dissociation that can happen during and shortly after dosing.

IV Ketamine vs Spravato Effectiveness: Which Works Better?

Research suggests both treatments can meaningfully reduce depressive symptoms, but the evidence on which works "better" is still developing and more nuanced than most marketing suggests.

A 2020 randomized trial by Correia-Melo and colleagues found esketamine was statistically non-inferior to IV ketamine at 24 hours, with remission rates of about 24.1% for ketamine versus 29.4% for esketamine in a small sample. (Correia-Melo et al., 2020)

However, a larger 2021 meta-analysis by Bahji and colleagues, reviewing 24 randomized trials and nearly 1,900 patients, found racemic IV ketamine was associated with higher response and remission rates than esketamine, along with lower dropout, though the authors caution that direct head-to-head trials remain limited. (Bahji et al., 2021, PMC)

Here's what current research generally points to:

• For treatment-resistant depression: both may produce meaningful symptom relief within days
• For suicidal ideation: Spravato has an FDA-approved indication specifically for MDD with acute suicidal ideation, though the FDA notes it hasn't been proven to prevent suicide itself
• Duration of benefits: effects from a single session tend to fade over days to weeks for both, which is why an ongoing plan matters more than any single appointment
• Individual response varies significantly. What works well for one person may not work as well for another

No large-scale, definitive head-to-head trial has settled which treatment is more effective. Most comparative data comes from smaller trials or indirect meta-analyses. We recommend being skeptical before trusting any treatment to be the better one.

If you're curious how ketamine performs against other established depression treatments, this related comparison of ketamine versus ECT in depression is worth a read.

Side Effects and Safety Comparison

Both treatments share a similar short-term side effect profile since they act on the same receptor system, though the frequency of certain effects appears to differ.

Common IV ketamine side effects:

• Dissociation (feeling detached from your body or surroundings)
• Increased blood pressure
• Dizziness
• Nausea
• Sedation

Common Spravato side effects:

• Dissociation and depersonalization
• Dizziness
• Sedation
• Increased blood pressure
• Nausea and vomiting

A 2025 systematic review comparing safety data found IV ketamine was associated with higher rates of dissociation (58% vs. 34%), hypertension (45% vs. 9.2%), dizziness (30% vs. 6.3%), and sedation (50% vs. 27%) compared to esketamine, while esketamine showed somewhat higher rates of nausea and depersonalization.

Read more on the safety and tolerability of the two treatments in this PMC review.

Potential for abuse: Both ketamine and esketamine are Schedule III controlled substances due to recognized misuse potential, which is part of why both require in-clinic administration rather than take-home prescriptions.

Contraindications for either treatment generally include uncontrolled hypertension, certain heart conditions, active psychosis, and pregnancy, though your prescribing physician will screen your full medical history before recommending either option.

Long-term safety data for both treatments, especially beyond a year or two of maintenance dosing, is still relatively limited, so ongoing monitoring by your care team matters.

Cost Comparison: Ketamine Infusion vs Spravato

Cost is often the deciding factor for many people weighing IV ketamine against Spravato, and the numbers look quite different once insurance enters the picture.

IV ketamine typically costs $400 to $800 per infusion, with an initial induction series of six infusions running roughly $2,400 to $4,200 out of pocket. Because it's off-label, it's rarely covered by insurance. (Lumin Health cost guide)

Spravato costs roughly $590 to $885 for the drug itself per session, plus a monitoring fee, bringing the cash-pay total to around $1,000 to $1,500 per session. Reported Medicare reimbursement has ranged from about $951 to $1,353 per session. (HealingMaps Spravato cost breakdown)

The key difference comes down to insurance coverage:

• Spravato is often covered by commercial insurance and Medicare when a patient meets treatment-resistant depression criteria, since it's an FDA-approved treatment
• IV ketamine is usually not covered because depression use remains off-label, though some clinics offer payment plans or financing
• Out-of-pocket costs for a full initial series can run into the thousands for either option, so it's worth asking any clinic for a detailed cost breakdown before starting
• Financial assistance: some Spravato patients may qualify for manufacturer savings programs; ketamine clinics vary widely on whether they offer sliding-scale or package pricing

‍

If cost and coverage are a major concern for you, ask your prospective clinic directly what a full initial series and maintenance schedule would realistically cost, including any hidden monitoring or facility fees.

‍

Who Is a Good Candidate for Each Treatment?

Both treatments are generally considered for people who haven't found relief with standard antidepressants, but a few factors help guide which direction your doctor might lean.

You may be a candidate for either treatment if you have:

• Treatment-resistant depression (typically defined as not responding to two or more antidepressant trials)
• Major depressive disorder that hasn't improved with standard care
• Depression accompanied by suicidal thoughts (Spravato has a specific FDA-approved indication here)

A few more things to consider:

• Bipolar depression is sometimes treated off-label with ketamine under close psychiatric supervision, though this requires careful screening for mania risk
• Your full medical history, including blood pressure, cardiac history, and substance use history, will factor into which option is safer for you
• A documented history of failed antidepressant trials is typically required before either treatment is considered

Spravato tends to be recommended when a patient wants insurance coverage, prefers a standardized FDA-approved protocol, or has an active REMS-certified provider nearby. IV ketamine tends to be recommended when a patient wants more flexible dosing, has already tried Spravato without full relief, or is also managing chronic pain alongside depression.

If postpartum depression is part of your situation, this piece on ketamine for postpartum depression will give you more clarity on this specific use case.

Pros and Cons of IV Ketamine and Spravato

Weighing the tradeoffs side by side can make this decision feel a little less overwhelming.

Which Is Better: Spravato or Ketamine Infusion?

Choosing between IV ketamine and Spravato depends on your diagnosis, treatment history, insurance coverage, budget, and your healthcare provider's recommendation. Neither treatment is universally better, but one may be a better fit for your individual needs.

Here's how they stack up on the factors people ask about most:

• Effectiveness: Some studies suggest IV ketamine may edge out esketamine in response and remission rates, but evidence is mixed and head-to-head trials are limited
• Affordability without insurance: IV ketamine is generally cheaper per session
• Insurance coverage: Spravato wins here since it's FDA-approved
• Speed of relief: Both can act within hours to days; neither has a clearly proven edge
• Clinical evidence base: Spravato has more standardized, FDA-reviewed trial data; IV ketamine has decades of anesthesia safety data plus a growing off-label psychiatric literature
• Convenience: IV ketamine sessions are typically shorter; Spravato requires the mandatory 2-hour observation
• Physician recommendation: Often the deciding factor, since your doctor knows your full medical picture

The honest answer is that the "better" option is the one that fits your specific diagnosis, financial situation, and what a psychiatrist familiar with your history recommends after an evaluation.

Final Verdict: IV Ketamine vs Spravato

When comparing IV ketamine vs Spravato, the right choice depends on your medical condition, treatment goals, insurance coverage, and physician's guidance. Understanding the differences can help you make a more informed decision about your mental health care.

The biggest differences come down to formulation (full ketamine molecule vs. isolated esketamine), approval status (off-label vs. FDA-approved), and cost structure (cheaper per session vs. more likely to be insured).

Klearmind's physician-led team, overseen by anesthesiologists with inpatient ketamine backgrounds, evaluates each patient individually before recommending ketamine-assisted therapy or referring Spravato when it's a better clinical fit.

Whichever direction you're leaning, talk to a qualified psychiatrist before starting either treatment; your diagnosis and history should drive the decision, not cost or convenience alone.

FAQs

Is Spravato the same as ketamine?

Not exactly. Spravato contains esketamine, which is only one half (the S-enantiomer) of the full ketamine molecule used in IV infusions. They share a chemical origin and act on the same brain receptors, but they're formulated and approved differently.

Is Spravato actually ketamine?

Spravato is derived from ketamine but isn't identical to it. It's a distinct, FDA-approved medication made from esketamine, the isolated S-ketamine component, rather than the racemic (full) ketamine molecule used in IV infusions.

What is the difference between IV ketamine and Spravato?

IV ketamine is an off-label infusion using the complete ketamine molecule, given intravenously at a clinic. Spravato is an FDA-approved nasal spray containing only esketamine, administered under REMS monitoring with a mandatory 2-hour observation period.

Which is better: Spravato vs ketamine infusion?

Neither is universally better. Research suggests IV ketamine may show somewhat stronger response rates in some studies, while Spravato offers FDA approval and more consistent insurance coverage. The right choice depends on your diagnosis, budget, and your psychiatrist's recommendation.

Is ketamine infusion more effective than Spravato?

Some studies, including a 2021 meta-analysis, found racemic IV ketamine associated with higher response and remission rates than esketamine. However, direct head-to-head trials remain limited, so this isn't a settled conclusion, and individual response varies.

How much does IV ketamine cost compared to Spravato?

IV ketamine typically runs $400 to $800 per session, with a six-infusion series costing $2,400 to $4,200 out of pocket. Spravato usually costs $1,000 to $1,500 per session when paying cash, though insurance coverage can significantly lower that amount.

Does insurance cover Spravato but not IV ketamine?

Often, yes. Because Spravato is FDA-approved for treatment-resistant depression, many commercial insurance plans and Medicare cover it when criteria are met. IV ketamine is generally not covered since its use for depression remains off-label.

How long do the effects of Spravato and IV ketamine last?

Effects from a single session for either treatment often fade over days to a few weeks, which is why most people need an initial series followed by ongoing maintenance sessions. Duration varies significantly from person to person.

Who qualifies for Spravato treatment?

Spravato is FDA-approved for adults with treatment-resistant depression (used alongside an oral antidepressant) and for major depressive disorder with acute suicidal ideation or behavior. A psychiatrist will confirm eligibility based on your treatment history and medical background.

What are the side effects of ketamine infusion vs Spravato?

Both share side effects like dissociation, dizziness, nausea, sedation, and temporary blood pressure increases. Comparative data suggests IV ketamine may cause dissociation and blood pressure changes somewhat more often, while esketamine has shown slightly higher rates of nausea in some studies.

Can IV ketamine and Spravato treat treatment-resistant depression?

Yes. Both are used for treatment-resistant depression, IV ketamine off-label and Spravato under FDA approval. Both are typically considered after standard antidepressants haven't provided sufficient relief.

How quickly do IV ketamine and Spravato start working?

Both can begin working faster than traditional antidepressants, sometimes within hours to a few days for some patients, compared to the 2-6 weeks typically needed for SSRIs. Individual response times still vary.

‍